Olivia del Valle, NP
Family · Lillington, NCNPI 1245822865
Payments from drug & device makers
Across 136 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$575
- Lilly USA, LLC$169
- Merck$156
- Johnson & Johnson$136
- Mylan Specialty L.p.$112
- Theratechnologies Inc.$102
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,385100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $575 |
| Lilly USA, LLC | 10 | $169 |
| Merck | 9 | $156 |
| Johnson & Johnson(2 entities) | 8 | $136 |
| Mylan Specialty L.p. | 5 | $112 |
| Theratechnologies Inc. | 4 | $102 |
| Exact Sciences | 5 | $100 |
| AbbVie | 5 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $77 |
| Paratek Pharmaceuticals, Inc. | 4 | $77 |
| Viiv Healthcare Company | 3 | $75 |
| Boehringer Ingelheim | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Pfizer | 3 | $48 |
| Melinta Therapeutics, LLC | 2 | $47 |
| Gilead | 2 | $45 |
| GSK | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $39 |
| Novartis | 2 | $35 |
| Shionogi Inc | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Amgen | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Medtronic | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$2,385 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $74,937 |
| OzempicSemaglutide | 44 | $51,533 |
| TrulicityDulaglutide | 31 | $34,960 |
| XareltoRivaroxaban | 24 | $24,671 |
| JardianceEmpagliflozin | 15 | $20,624 |
| FarxigaDapagliflozin Propanediol | 11 | $12,999 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $11,690 |
| MounjaroTirzepatide | 11 | $11,305 |
| JanuviaSitagliptin Phosphate | 16 | $8,671 |
| Spiriva HandihalerTiotropium Bromide | 14 | $8,237 |
| MyrbetriqMirabegron | 18 | $7,949 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,226 |
| Levemir FlexpenInsulin Detemir | 15 | $3,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $2,669 |
| Atorvastatin Calcium | 271 | $2,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $74,93778 claims |
| Novo NordiskOzempic | $575 | $51,53344 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $169 | $46,26542 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $73 | $26,85027 claims |
| Johnson & JohnsonXarelto | $136 | $24,67124 claims |
| AstraZenecaFarxiga | $18 | $12,99911 claims |
| GSKBreo Ellipta | $39 | $11,69027 claims |
| MerckJanuvia | $156 | $8,67116 claims |
| AbbVieSynthroid | $86 | $94714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Lillington
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.